EDGEMOND JAMES sold $480K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 844 shares of UNITED THERAPEUTICS Corp (UTHR) at $568.90 ($0.48M total) on 2026-05-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may slightly influence sentiment, but the pre-arranged nature typically lowers the probability of a fundamental-information signal.
Market read
A routine 10b5-1 insider sale disclosure; sentiment impact is likely small unless corroborated by additional news.
What to watch
The filing does not disclose intent beyond the plan; traders should check for other insider buys/sells around the same period and any concurrent company-specific news.
Background
SEC Form 4 reports insider transactions by officers/directors/10%-owners; these are often scheduled under Rule 10b5-1 to manage trading compliance.
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold 844 shares in an open-market transaction disclosed on SEC Form 4.
Likely limited near-term impact; any effect should be small and fade unless accompanied by other fundamental news.
This is a routine Form 4 disclosure with a stated pre-arranged 10b5-1 plan, providing limited incremental information about company fundamentals.
Market effects
No direct read-across; insider Form 4s typically have limited sector spillover absent concurrent fundamental catalysts.
Minimal; US-listed biotech-specific ownership disclosure with no broader market linkage.
Low; event is company-specific and not tied to global regulatory or trial milestones.
Counterpoint
A 10b5-1 plan sale can be purely mechanical (tax/portfolio rebalancing) and may not reflect bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the insider transaction disclosure; CFO/treasurer sold shares via open-market sale under a 10b5-1 plan.
- insiderEdgemond James
CFO and treasurer who executed the sale of 844 shares at ~$568.90.
